Pharmacotherapeutics for Veterinary Dispensing 2019
DOI: 10.1002/9781119404576.ch14
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacotherapeutics of Immune‐Mediated Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 105 publications
0
1
0
Order By: Relevance
“…Leflunomide may be particularly toxic to activated T cells, which mainly generate pyrimidines through the de novo route [4]. Blockade of tumor necrosis factor is one of the leflunomide's immunomodulatory and anti-inflammatory actions, which have recently been reviewed [5]. Reactive oxygen radicals [6] are inhibited by mediated activation of the transcription factor NFêB.…”
Section: Leflunomidementioning
confidence: 99%
“…Leflunomide may be particularly toxic to activated T cells, which mainly generate pyrimidines through the de novo route [4]. Blockade of tumor necrosis factor is one of the leflunomide's immunomodulatory and anti-inflammatory actions, which have recently been reviewed [5]. Reactive oxygen radicals [6] are inhibited by mediated activation of the transcription factor NFêB.…”
Section: Leflunomidementioning
confidence: 99%